| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 61 | 2023 | 3168 | 2.740 |
Why?
|
| Lung Neoplasms | 112 | 2023 | 11538 | 2.720 |
Why?
|
| Pneumonectomy | 43 | 2023 | 831 | 2.510 |
Why?
|
| Esophagectomy | 37 | 2022 | 911 | 2.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 70 | 2023 | 5319 | 2.310 |
Why?
|
| Thoracic Surgical Procedures | 10 | 2022 | 261 | 1.360 |
Why?
|
| Adenocarcinoma | 43 | 2023 | 7789 | 1.130 |
Why?
|
| Pleural Neoplasms | 14 | 2021 | 470 | 0.970 |
Why?
|
| Neoadjuvant Therapy | 33 | 2023 | 4975 | 0.940 |
Why?
|
| Thoracic Surgery | 5 | 2016 | 295 | 0.910 |
Why?
|
| Neoplasm Staging | 77 | 2023 | 13658 | 0.880 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2021 | 565 | 0.860 |
Why?
|
| Metastasectomy | 5 | 2023 | 200 | 0.790 |
Why?
|
| Middle Aged | 197 | 2022 | 86204 | 0.760 |
Why?
|
| Postoperative Complications | 36 | 2022 | 5542 | 0.740 |
Why?
|
| Thoracic Vertebrae | 9 | 2020 | 186 | 0.730 |
Why?
|
| Aged | 170 | 2021 | 70117 | 0.710 |
Why?
|
| Retrospective Studies | 101 | 2023 | 37905 | 0.710 |
Why?
|
| Surgical Flaps | 11 | 2020 | 927 | 0.680 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 170 | 0.680 |
Why?
|
| Humans | 282 | 2023 | 261506 | 0.650 |
Why?
|
| Spinal Neoplasms | 12 | 2020 | 631 | 0.630 |
Why?
|
| Lung Diseases | 5 | 2021 | 717 | 0.600 |
Why?
|
| Male | 184 | 2022 | 123000 | 0.590 |
Why?
|
| Thoracic Neoplasms | 7 | 2018 | 337 | 0.590 |
Why?
|
| Mesothelioma | 11 | 2018 | 544 | 0.590 |
Why?
|
| Jejunum | 4 | 2015 | 216 | 0.550 |
Why?
|
| Female | 194 | 2022 | 141928 | 0.550 |
Why?
|
| Trachea | 4 | 2015 | 259 | 0.550 |
Why?
|
| Carcinoma, Squamous Cell | 28 | 2021 | 5437 | 0.550 |
Why?
|
| Treatment Outcome | 78 | 2023 | 32848 | 0.540 |
Why?
|
| Thoracic Surgery, Video-Assisted | 8 | 2022 | 209 | 0.540 |
Why?
|
| Thymus Neoplasms | 7 | 2020 | 400 | 0.530 |
Why?
|
| Survival Rate | 55 | 2023 | 12221 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 37 | 2021 | 10035 | 0.520 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 672 | 0.510 |
Why?
|
| Sarcoma | 11 | 2018 | 1725 | 0.510 |
Why?
|
| Pain, Postoperative | 4 | 2021 | 610 | 0.510 |
Why?
|
| Thoracic Wall | 4 | 2020 | 183 | 0.500 |
Why?
|
| Adult | 138 | 2021 | 77950 | 0.490 |
Why?
|
| Esophagogastric Junction | 8 | 2023 | 543 | 0.480 |
Why?
|
| Combined Modality Therapy | 47 | 2023 | 8865 | 0.470 |
Why?
|
| Esophagus | 4 | 2015 | 553 | 0.450 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2021 | 1226 | 0.450 |
Why?
|
| Tracheal Neoplasms | 2 | 2010 | 42 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 37 | 2023 | 15862 | 0.430 |
Why?
|
| Colorectal Neoplasms | 7 | 2023 | 3578 | 0.400 |
Why?
|
| Pain Management | 3 | 2021 | 668 | 0.400 |
Why?
|
| Thoracotomy | 8 | 2022 | 220 | 0.390 |
Why?
|
| Aged, 80 and over | 63 | 2021 | 29902 | 0.390 |
Why?
|
| Prognosis | 49 | 2023 | 21713 | 0.390 |
Why?
|
| Cardiology | 1 | 2016 | 530 | 0.370 |
Why?
|
| Bronchi | 11 | 2008 | 326 | 0.370 |
Why?
|
| Thymoma | 5 | 2017 | 246 | 0.370 |
Why?
|
| Survival Analysis | 37 | 2019 | 9180 | 0.370 |
Why?
|
| Disease-Free Survival | 31 | 2021 | 10001 | 0.360 |
Why?
|
| Risk Assessment | 15 | 2021 | 6869 | 0.360 |
Why?
|
| Patient Selection | 10 | 2021 | 2055 | 0.360 |
Why?
|
| Follow-Up Studies | 39 | 2021 | 14889 | 0.360 |
Why?
|
| Research Report | 1 | 2011 | 144 | 0.360 |
Why?
|
| Databases, Factual | 11 | 2020 | 2218 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 13 | 2019 | 3981 | 0.340 |
Why?
|
| Tretinoin | 9 | 2007 | 623 | 0.340 |
Why?
|
| Time Factors | 28 | 2021 | 12926 | 0.340 |
Why?
|
| Induction Chemotherapy | 3 | 2018 | 669 | 0.340 |
Why?
|
| Surgical Wound Infection | 4 | 2017 | 450 | 0.330 |
Why?
|
| Bupivacaine | 2 | 2020 | 68 | 0.330 |
Why?
|
| Thoracoplasty | 2 | 2020 | 20 | 0.330 |
Why?
|
| Texas | 20 | 2019 | 6311 | 0.330 |
Why?
|
| Propensity Score | 8 | 2021 | 750 | 0.320 |
Why?
|
| Mediastinal Neoplasms | 3 | 2010 | 423 | 0.320 |
Why?
|
| Microsurgery | 1 | 2010 | 244 | 0.320 |
Why?
|
| Surgical Instruments | 2 | 2008 | 138 | 0.310 |
Why?
|
| Information Dissemination | 1 | 2011 | 272 | 0.310 |
Why?
|
| Prosthesis Implantation | 2 | 2010 | 263 | 0.310 |
Why?
|
| Preoperative Care | 14 | 2019 | 1529 | 0.310 |
Why?
|
| Lymph Nodes | 7 | 2021 | 2967 | 0.300 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 992 | 0.300 |
Why?
|
| Salvage Therapy | 9 | 2021 | 2054 | 0.300 |
Why?
|
| Osteotomy | 3 | 2020 | 100 | 0.300 |
Why?
|
| Positron-Emission Tomography | 7 | 2021 | 2173 | 0.300 |
Why?
|
| Multivariate Analysis | 20 | 2019 | 4298 | 0.290 |
Why?
|
| Patient Discharge | 3 | 2021 | 661 | 0.280 |
Why?
|
| Radiotherapy, Adjuvant | 16 | 2017 | 2231 | 0.280 |
Why?
|
| Receptors, Retinoic Acid | 8 | 2003 | 365 | 0.270 |
Why?
|
| Medical Errors | 1 | 2008 | 219 | 0.270 |
Why?
|
| Terminology as Topic | 1 | 2008 | 414 | 0.260 |
Why?
|
| Radiopharmaceuticals | 8 | 2021 | 1301 | 0.260 |
Why?
|
| Thoracoscopy | 3 | 2005 | 101 | 0.260 |
Why?
|
| Ipilimumab | 4 | 2023 | 710 | 0.260 |
Why?
|
| Robotic Surgical Procedures | 3 | 2021 | 481 | 0.260 |
Why?
|
| Lung | 9 | 2023 | 3151 | 0.260 |
Why?
|
| Neoplasm Seeding | 2 | 1995 | 66 | 0.260 |
Why?
|
| Genes, p53 | 5 | 2003 | 1090 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2018 | 7551 | 0.250 |
Why?
|
| Chemoradiotherapy | 6 | 2021 | 1946 | 0.240 |
Why?
|
| Risk Factors | 20 | 2023 | 17523 | 0.240 |
Why?
|
| Camptothecin | 5 | 2004 | 517 | 0.240 |
Why?
|
| Continuity of Patient Care | 2 | 2016 | 225 | 0.230 |
Why?
|
| Endosonography | 5 | 2009 | 536 | 0.230 |
Why?
|
| Postoperative Care | 5 | 2021 | 739 | 0.230 |
Why?
|
| Stomach Neoplasms | 6 | 2023 | 2278 | 0.220 |
Why?
|
| Surgical Mesh | 3 | 2016 | 209 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 16 | 2021 | 3890 | 0.220 |
Why?
|
| Smoking Cessation | 3 | 2021 | 712 | 0.220 |
Why?
|
| Predictive Value of Tests | 10 | 2020 | 4892 | 0.210 |
Why?
|
| Adenoviridae | 5 | 2003 | 1459 | 0.210 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 1371 | 0.210 |
Why?
|
| Length of Stay | 11 | 2018 | 1900 | 0.210 |
Why?
|
| Esophagoplasty | 2 | 2012 | 27 | 0.210 |
Why?
|
| Prospective Studies | 21 | 2022 | 12873 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2019 | 6207 | 0.200 |
Why?
|
| Pleura | 2 | 2021 | 127 | 0.200 |
Why?
|
| Cohort Studies | 17 | 2019 | 9244 | 0.200 |
Why?
|
| Intercostal Nerves | 2 | 2020 | 33 | 0.200 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 24 | 0.200 |
Why?
|
| Cisplatin | 20 | 2013 | 2432 | 0.200 |
Why?
|
| Epidemiologic Methods | 3 | 2018 | 254 | 0.200 |
Why?
|
| Melanoma | 4 | 2023 | 5317 | 0.190 |
Why?
|
| Fluorouracil | 18 | 2017 | 1944 | 0.190 |
Why?
|
| Neoplasm, Residual | 5 | 2018 | 1656 | 0.190 |
Why?
|
| Patient Readmission | 3 | 2021 | 548 | 0.190 |
Why?
|
| Perioperative Care | 3 | 2019 | 451 | 0.190 |
Why?
|
| Smoking | 9 | 2021 | 2440 | 0.190 |
Why?
|
| Biopsy | 6 | 2020 | 3443 | 0.190 |
Why?
|
| Esophagoscopy | 3 | 2021 | 291 | 0.190 |
Why?
|
| Hospital Mortality | 3 | 2018 | 1274 | 0.190 |
Why?
|
| Hemorrhage | 4 | 2019 | 712 | 0.190 |
Why?
|
| Breast Neoplasms | 19 | 2015 | 15694 | 0.180 |
Why?
|
| Anesthetics, Local | 2 | 2020 | 163 | 0.180 |
Why?
|
| Respiratory Function Tests | 2 | 2018 | 318 | 0.180 |
Why?
|
| Young Adult | 20 | 2020 | 21445 | 0.180 |
Why?
|
| Germinoma | 1 | 2000 | 84 | 0.180 |
Why?
|
| Incidence | 10 | 2021 | 5673 | 0.180 |
Why?
|
| Genetic Therapy | 5 | 2003 | 1616 | 0.170 |
Why?
|
| Nerve Block | 2 | 2020 | 176 | 0.170 |
Why?
|
| Radiosurgery | 2 | 2019 | 1330 | 0.170 |
Why?
|
| Informed Consent | 1 | 2022 | 419 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 162 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 709 | 0.170 |
Why?
|
| Lymphatic Metastasis | 11 | 2021 | 4844 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 5061 | 0.160 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2019 | 94 | 0.160 |
Why?
|
| Respiratory Mucosa | 3 | 2007 | 206 | 0.160 |
Why?
|
| Chondrosarcoma | 1 | 2020 | 216 | 0.160 |
Why?
|
| Gene Transfer Techniques | 7 | 2003 | 716 | 0.160 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 4988 | 0.160 |
Why?
|
| Adolescent | 23 | 2021 | 31252 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 915 | 0.160 |
Why?
|
| Cross Infection | 2 | 2018 | 544 | 0.150 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 280 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2018 | 119 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 360 | 0.150 |
Why?
|
| Medical Records | 1 | 2018 | 415 | 0.150 |
Why?
|
| Hemoptysis | 1 | 1997 | 36 | 0.150 |
Why?
|
| Diaphragm | 2 | 2017 | 181 | 0.150 |
Why?
|
| Genetic Vectors | 6 | 2003 | 1694 | 0.150 |
Why?
|
| Ticlopidine | 1 | 2017 | 95 | 0.150 |
Why?
|
| Logistic Models | 7 | 2019 | 3441 | 0.150 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 629 | 0.150 |
Why?
|
| Stomach | 2 | 2012 | 387 | 0.150 |
Why?
|
| Lasers | 2 | 1998 | 198 | 0.150 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10331 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.150 |
Why?
|
| Radiography | 5 | 2014 | 1904 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 113 | 0.140 |
Why?
|
| Anticarcinogenic Agents | 3 | 2007 | 362 | 0.140 |
Why?
|
| Sternum | 2 | 1995 | 100 | 0.140 |
Why?
|
| Gastrectomy | 3 | 2023 | 451 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 821 | 0.140 |
Why?
|
| Analgesia, Epidural | 1 | 2017 | 102 | 0.140 |
Why?
|
| Chi-Square Distribution | 7 | 2017 | 1323 | 0.140 |
Why?
|
| Research Design | 2 | 2022 | 1544 | 0.140 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1995 | 34 | 0.140 |
Why?
|
| Acellular Dermis | 1 | 2017 | 103 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 2 | 2013 | 383 | 0.130 |
Why?
|
| Pectoralis Muscles | 1 | 2015 | 27 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 160 | 0.130 |
Why?
|
| Bronchoscopy | 7 | 2003 | 474 | 0.130 |
Why?
|
| Tissue Adhesives | 2 | 2004 | 51 | 0.130 |
Why?
|
| Bone Neoplasms | 4 | 2011 | 2576 | 0.130 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 569 | 0.130 |
Why?
|
| DNA, Neoplasm | 4 | 2017 | 1910 | 0.130 |
Why?
|
| Teratoma | 1 | 1997 | 236 | 0.130 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2010 | 52 | 0.130 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 235 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 4 | 2011 | 945 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 441 | 0.120 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 622 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 2403 | 0.120 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2014 | 17 | 0.120 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2014 | 31 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 574 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2019 | 787 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 444 | 0.120 |
Why?
|
| Remission Induction | 11 | 2017 | 3569 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2009 | 749 | 0.120 |
Why?
|
| Heart Neoplasms | 2 | 2009 | 214 | 0.120 |
Why?
|
| Mutation | 4 | 2019 | 15179 | 0.120 |
Why?
|
| Cancer Care Facilities | 4 | 2018 | 884 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2003 | 639 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 1997 | 636 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 1303 | 0.110 |
Why?
|
| Trastuzumab | 1 | 2015 | 696 | 0.110 |
Why?
|
| Goserelin | 1 | 2012 | 18 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 1993 | 57 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 5687 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 739 | 0.110 |
Why?
|
| Antineoplastic Agents | 12 | 2015 | 14289 | 0.110 |
Why?
|
| Analysis of Variance | 8 | 2018 | 2307 | 0.110 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2013 | 121 | 0.110 |
Why?
|
| Menstruation | 1 | 2012 | 39 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 2864 | 0.110 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 152 | 0.110 |
Why?
|
| Drug Administration Schedule | 8 | 2019 | 3472 | 0.110 |
Why?
|
| Premedication | 3 | 2005 | 135 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2008 | 311 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 1995 | 361 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2006 | 1823 | 0.110 |
Why?
|
| Premenopause | 1 | 2012 | 131 | 0.110 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 71 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 4 | 2006 | 1350 | 0.100 |
Why?
|
| Omentum | 1 | 2012 | 96 | 0.100 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 146 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 1331 | 0.100 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 58 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.100 |
Why?
|
| Liposomes | 3 | 2017 | 684 | 0.100 |
Why?
|
| Neurosurgical Procedures | 2 | 2010 | 609 | 0.100 |
Why?
|
| Policy Making | 1 | 2011 | 85 | 0.100 |
Why?
|
| Tracheostomy | 2 | 2010 | 243 | 0.100 |
Why?
|
| Epithelial Cells | 5 | 2021 | 1818 | 0.100 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 69 | 0.100 |
Why?
|
| Pathology, Surgical | 1 | 2011 | 81 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2003 | 142 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2011 | 719 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2011 | 425 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2009 | 1216 | 0.090 |
Why?
|
| Liver Neoplasms | 7 | 2011 | 4557 | 0.090 |
Why?
|
| Thyroid Neoplasms | 2 | 2006 | 1866 | 0.090 |
Why?
|
| Osteomyelitis | 1 | 1993 | 236 | 0.090 |
Why?
|
| Pancoast Syndrome | 2 | 2000 | 9 | 0.090 |
Why?
|
| Vascular Neoplasms | 2 | 2009 | 114 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 498 | 0.090 |
Why?
|
| Isotretinoin | 2 | 2007 | 158 | 0.090 |
Why?
|
| Disease Progression | 10 | 2020 | 6682 | 0.090 |
Why?
|
| Tomography, Emission-Computed | 3 | 2008 | 310 | 0.090 |
Why?
|
| Treatment Failure | 5 | 2017 | 1391 | 0.090 |
Why?
|
| Observer Variation | 1 | 2011 | 671 | 0.090 |
Why?
|
| Vena Cava, Inferior | 2 | 2003 | 190 | 0.090 |
Why?
|
| Reoperation | 4 | 2019 | 1382 | 0.090 |
Why?
|
| Thymectomy | 3 | 2020 | 79 | 0.090 |
Why?
|
| Metaplasia | 5 | 2021 | 383 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2017 | 4078 | 0.090 |
Why?
|
| Pulmonary Artery | 3 | 2009 | 499 | 0.090 |
Why?
|
| Chromosome Deletion | 2 | 2008 | 1005 | 0.090 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 980 | 0.080 |
Why?
|
| Neoplasms | 7 | 2023 | 15193 | 0.080 |
Why?
|
| Feasibility Studies | 5 | 2021 | 2292 | 0.080 |
Why?
|
| Precancerous Conditions | 3 | 2003 | 1058 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1021 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 643 | 0.080 |
Why?
|
| Surgeons | 1 | 2016 | 519 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 1586 | 0.080 |
Why?
|
| Abdomen | 2 | 2005 | 332 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2003 | 371 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2020 | 1987 | 0.080 |
Why?
|
| Ovary | 1 | 2012 | 668 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2291 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2010 | 228 | 0.080 |
Why?
|
| Telephone | 2 | 2021 | 163 | 0.080 |
Why?
|
| Spine | 2 | 2020 | 293 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 482 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2021 | 2316 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 135 | 0.080 |
Why?
|
| Vinblastine | 3 | 2008 | 453 | 0.080 |
Why?
|
| Paclitaxel | 7 | 2004 | 1996 | 0.080 |
Why?
|
| Epirubicin | 6 | 2009 | 157 | 0.080 |
Why?
|
| Anastomosis, Surgical | 4 | 2012 | 371 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 2 | 2001 | 408 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 652 | 0.080 |
Why?
|
| Retinoids | 3 | 1997 | 164 | 0.080 |
Why?
|
| Aprotinin | 1 | 2007 | 34 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 348 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2007 | 78 | 0.080 |
Why?
|
| Organoplatinum Compounds | 2 | 2013 | 702 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 328 | 0.080 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2010 | 255 | 0.080 |
Why?
|
| Peritonitis | 1 | 1988 | 89 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2011 | 1335 | 0.080 |
Why?
|
| Adenofibroma | 1 | 2007 | 20 | 0.080 |
Why?
|
| Drainage | 2 | 2000 | 416 | 0.080 |
Why?
|
| Neoplasm Metastasis | 7 | 2021 | 5112 | 0.070 |
Why?
|
| Intraoperative Complications | 3 | 2010 | 301 | 0.070 |
Why?
|
| Hemostatics | 1 | 2007 | 88 | 0.070 |
Why?
|
| Cyclophosphamide | 8 | 2009 | 3001 | 0.070 |
Why?
|
| Hemostasis | 1 | 2007 | 109 | 0.070 |
Why?
|
| Pneumonia, Aspiration | 1 | 2006 | 41 | 0.070 |
Why?
|
| Pain Measurement | 3 | 2020 | 953 | 0.070 |
Why?
|
| Factor XIII | 1 | 1986 | 8 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5178 | 0.070 |
Why?
|
| Physicians | 2 | 2014 | 882 | 0.070 |
Why?
|
| Sex Factors | 3 | 2020 | 2139 | 0.070 |
Why?
|
| Doxorubicin | 4 | 2009 | 3005 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2009 | 429 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2000 | 726 | 0.070 |
Why?
|
| Genes, p16 | 1 | 2006 | 125 | 0.070 |
Why?
|
| Spinal Fusion | 3 | 2010 | 149 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.070 |
Why?
|
| Methylmethacrylate | 3 | 2000 | 15 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 690 | 0.070 |
Why?
|
| Forearm | 1 | 2006 | 67 | 0.070 |
Why?
|
| Thrombin | 1 | 1986 | 99 | 0.070 |
Why?
|
| Neutropenia | 2 | 2009 | 968 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2518 | 0.070 |
Why?
|
| Fluorescence | 2 | 1998 | 195 | 0.070 |
Why?
|
| Patient Care Team | 3 | 2004 | 795 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2018 | 4744 | 0.070 |
Why?
|
| Cell Cycle Proteins | 3 | 1999 | 2045 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2000 | 852 | 0.070 |
Why?
|
| Fibrinogen | 1 | 1986 | 205 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1085 | 0.060 |
Why?
|
| Radiography, Thoracic | 3 | 2017 | 462 | 0.060 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 611 | 0.060 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2005 | 129 | 0.060 |
Why?
|
| Thrombosis | 3 | 2003 | 781 | 0.060 |
Why?
|
| Heterografts | 2 | 2019 | 733 | 0.060 |
Why?
|
| United States | 6 | 2020 | 15433 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 87 | 0.060 |
Why?
|
| Radiotherapy Dosage | 7 | 2007 | 3842 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1742 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2003 | 3552 | 0.060 |
Why?
|
| Signal Transduction | 9 | 2018 | 11965 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 1294 | 0.060 |
Why?
|
| Infusions, Intravenous | 7 | 2002 | 1382 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2006 | 310 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 1988 | 479 | 0.060 |
Why?
|
| Spinal Diseases | 1 | 2004 | 125 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2009 | 1237 | 0.060 |
Why?
|
| DNA-Binding Proteins | 4 | 2003 | 4821 | 0.060 |
Why?
|
| Pneumonia | 2 | 2013 | 751 | 0.060 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2003 | 87 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 275 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 2 | 1997 | 418 | 0.060 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2002 | 422 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 2232 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2019 | 1869 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2010 | 2203 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2006 | 3101 | 0.050 |
Why?
|
| Palliative Care | 4 | 1998 | 2037 | 0.050 |
Why?
|
| Lumbar Vertebrae | 2 | 2001 | 245 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2003 | 158 | 0.050 |
Why?
|
| Age Factors | 4 | 2020 | 5377 | 0.050 |
Why?
|
| Mitomycin | 5 | 2008 | 208 | 0.050 |
Why?
|
| Child | 8 | 2018 | 29154 | 0.050 |
Why?
|
| Costs and Cost Analysis | 3 | 2010 | 306 | 0.050 |
Why?
|
| Income | 1 | 2023 | 222 | 0.050 |
Why?
|
| Radiotherapy, Conformal | 1 | 2007 | 902 | 0.050 |
Why?
|
| Cervical Vertebrae | 2 | 2000 | 205 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 103 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.050 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2005 | 421 | 0.050 |
Why?
|
| Penicillanic Acid | 1 | 2001 | 20 | 0.050 |
Why?
|
| Probability | 3 | 2010 | 866 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 1998 | 123 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2013 | 344 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 6 | 1 | 2000 | 7 | 0.050 |
Why?
|
| Ultrasonics | 1 | 2020 | 69 | 0.050 |
Why?
|
| Hospital Bed Capacity | 1 | 2000 | 27 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1998 | 206 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 2315 | 0.050 |
Why?
|
| Blotting, Northern | 5 | 2000 | 682 | 0.050 |
Why?
|
| Bone Substitutes | 1 | 2000 | 15 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2000 | 2359 | 0.050 |
Why?
|
| Fenretinide | 1 | 2000 | 96 | 0.050 |
Why?
|
| Registries | 2 | 2018 | 2170 | 0.040 |
Why?
|
| Cytokines | 2 | 2020 | 2809 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 259 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2001 | 130 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 162 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2002 | 193 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 485 | 0.040 |
Why?
|
| Pain, Intractable | 2 | 1998 | 171 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 756 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2001 | 223 | 0.040 |
Why?
|
| Endocarditis | 1 | 2000 | 125 | 0.040 |
Why?
|
| Transcription Factors | 3 | 1998 | 5270 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 289 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2002 | 560 | 0.040 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 1959 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2004 | 620 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2018 | 756 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 206 | 0.040 |
Why?
|
| Muscles | 3 | 1989 | 416 | 0.040 |
Why?
|
| Spinal Cord Compression | 1 | 2000 | 151 | 0.040 |
Why?
|
| Immunohistochemistry | 6 | 2007 | 7548 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 764 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 217 | 0.040 |
Why?
|
| Physician's Role | 1 | 2001 | 238 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 1998 | 43 | 0.040 |
Why?
|
| Biopsy, Needle | 4 | 2005 | 1363 | 0.040 |
Why?
|
| Carcinoma | 2 | 2011 | 2578 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2003 | 2326 | 0.040 |
Why?
|
| cdc25 Phosphatases | 1 | 1998 | 97 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 472 | 0.040 |
Why?
|
| Methods | 1 | 1997 | 189 | 0.040 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2000 | 156 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2003 | 2074 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2006 | 2086 | 0.040 |
Why?
|
| RNA, Messenger | 7 | 2003 | 6150 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 1999 | 335 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1998 | 182 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2000 | 435 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 1998 | 116 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 311 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 313 | 0.040 |
Why?
|
| Carboplatin | 3 | 2008 | 823 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 6 | 2003 | 5395 | 0.040 |
Why?
|
| Mediastinum | 1 | 2019 | 268 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 577 | 0.040 |
Why?
|
| Bone Plates | 3 | 2004 | 47 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 598 | 0.040 |
Why?
|
| Cyclin E | 1 | 1999 | 267 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 2283 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1998 | 214 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 1999 | 576 | 0.040 |
Why?
|
| Suture Techniques | 3 | 2007 | 319 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 649 | 0.040 |
Why?
|
| Sacrum | 1 | 1997 | 132 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2003 | 8873 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 1581 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 905 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 3 | 2009 | 1290 | 0.040 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 1026 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 363 | 0.040 |
Why?
|
| Ki-67 Antigen | 3 | 2007 | 666 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 1997 | 153 | 0.040 |
Why?
|
| Recurrence | 3 | 2005 | 4758 | 0.040 |
Why?
|
| Mitoxantrone | 4 | 2003 | 216 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.040 |
Why?
|
| Brachytherapy | 2 | 2003 | 977 | 0.040 |
Why?
|
| Laryngeal Masks | 1 | 1997 | 75 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2008 | 7702 | 0.040 |
Why?
|
| Thorax | 1 | 1997 | 213 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2003 | 1678 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2007 | 2104 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 534 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 1064 | 0.030 |
Why?
|
| Alcoholism | 1 | 1999 | 285 | 0.030 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 4971 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1997 | 290 | 0.030 |
Why?
|
| Keratolytic Agents | 1 | 1995 | 20 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2003 | 1411 | 0.030 |
Why?
|
| Diagnostic Imaging | 2 | 2001 | 1162 | 0.030 |
Why?
|
| Telomerase | 1 | 1999 | 525 | 0.030 |
Why?
|
| Retroviridae | 1 | 1996 | 332 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 1999 | 551 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2016 | 155 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 833 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 1996 | 246 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2019 | 1863 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1248 | 0.030 |
Why?
|
| Time | 1 | 2015 | 178 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Epithelium | 4 | 2000 | 720 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1999 | 803 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 2000 | 1320 | 0.030 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1994 | 41 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 1998 | 330 | 0.030 |
Why?
|
| Femoral Neoplasms | 1 | 1995 | 64 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 1994 | 45 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1163 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2003 | 301 | 0.030 |
Why?
|
| Tracheal Stenosis | 1 | 1994 | 38 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2012 | 551 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 1085 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 703 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1997 | 641 | 0.030 |
Why?
|
| Prevalence | 2 | 2018 | 3260 | 0.030 |
Why?
|
| Day Care, Medical | 1 | 2013 | 15 | 0.030 |
Why?
|
| Polyethylenes | 1 | 1993 | 12 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1998 | 318 | 0.030 |
Why?
|
| Necrosis | 1 | 1995 | 580 | 0.030 |
Why?
|
| Polypropylenes | 1 | 1993 | 25 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1998 | 810 | 0.030 |
Why?
|
| Transfection | 4 | 2003 | 2944 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1997 | 445 | 0.030 |
Why?
|
| Methotrexate | 4 | 2003 | 999 | 0.030 |
Why?
|
| Heart Arrest | 1 | 1998 | 358 | 0.030 |
Why?
|
| Exercise Test | 1 | 1994 | 312 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1022 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 1994 | 401 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1993 | 209 | 0.030 |
Why?
|
| Polyethylene Glycols | 2 | 2009 | 615 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 829 | 0.030 |
Why?
|
| Genes, Reporter | 3 | 2000 | 798 | 0.030 |
Why?
|
| Cells, Cultured | 5 | 2000 | 5637 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2006 | 3639 | 0.030 |
Why?
|
| Cell Survival | 2 | 2013 | 3045 | 0.030 |
Why?
|
| Manometry | 1 | 2012 | 74 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 752 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1997 | 607 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1995 | 588 | 0.030 |
Why?
|
| Pressure | 1 | 2012 | 215 | 0.030 |
Why?
|
| Critical Care | 1 | 1998 | 770 | 0.030 |
Why?
|
| Gastrointestinal Motility | 1 | 2012 | 92 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1993 | 660 | 0.030 |
Why?
|
| Abscess | 1 | 1993 | 177 | 0.030 |
Why?
|
| Bone Screws | 2 | 2004 | 84 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 4938 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1997 | 1130 | 0.020 |
Why?
|
| Patient Safety | 1 | 2017 | 649 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 1997 | 1143 | 0.020 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2295 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 3976 | 0.020 |
Why?
|
| Contrast Media | 2 | 2008 | 1472 | 0.020 |
Why?
|
| Dumping Syndrome | 1 | 2010 | 7 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2341 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2011 | 6100 | 0.020 |
Why?
|
| Cell Division | 3 | 2001 | 2489 | 0.020 |
Why?
|
| Health Policy | 1 | 2014 | 291 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 2000 | 6089 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 495 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 250 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Orthopedic Fixation Devices | 2 | 2001 | 20 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1997 | 1493 | 0.020 |
Why?
|
| Internal Fixators | 1 | 2010 | 14 | 0.020 |
Why?
|
| Oxygen | 1 | 1994 | 754 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 1546 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 131 | 0.020 |
Why?
|
| Mediastinoscopy | 1 | 2009 | 31 | 0.020 |
Why?
|
| Animals | 7 | 2019 | 59536 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2007 | 2588 | 0.020 |
Why?
|
| Reference Values | 2 | 2002 | 1099 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1998 | 2022 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5710 | 0.020 |
Why?
|
| Assisted Circulation | 1 | 1989 | 37 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2330 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 1997 | 1148 | 0.020 |
Why?
|
| DNA Damage | 1 | 1997 | 1954 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 111 | 0.020 |
Why?
|
| Bone Cements | 2 | 1999 | 45 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 1997 | 1664 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2000 | 448 | 0.020 |
Why?
|
| Filgrastim | 1 | 2009 | 191 | 0.020 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1989 | 167 | 0.020 |
Why?
|
| Hospital Charges | 2 | 2000 | 75 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Algorithms | 2 | 2011 | 3890 | 0.020 |
Why?
|
| Comorbidity | 2 | 2005 | 2352 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 447 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1988 | 68 | 0.020 |
Why?
|
| Hormones | 1 | 1989 | 266 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6009 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 1 | 1989 | 116 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2018 | 16273 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 356 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2009 | 2803 | 0.020 |
Why?
|
| Stents | 1 | 1994 | 1096 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 1988 | 90 | 0.020 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 4849 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 334 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 665 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2010 | 500 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1993 | 672 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1987 | 69 | 0.020 |
Why?
|
| Retinoid X Receptors | 2 | 1998 | 85 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2007 | 36 | 0.020 |
Why?
|
| Hemiplegia | 1 | 1987 | 47 | 0.020 |
Why?
|
| Proton Therapy | 1 | 2017 | 1577 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 298 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 1987 | 218 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 2007 | 83 | 0.020 |
Why?
|
| Kidney Neoplasms | 2 | 1998 | 3022 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 3230 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 2738 | 0.020 |
Why?
|
| Pericardium | 1 | 1987 | 157 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 1986 | 26 | 0.020 |
Why?
|
| Hand | 1 | 1987 | 170 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 144 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4549 | 0.020 |
Why?
|
| Tamoxifen | 1 | 1989 | 876 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1990 | 674 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 1998 | 3154 | 0.020 |
Why?
|
| Brachiocephalic Veins | 1 | 2004 | 21 | 0.020 |
Why?
|
| Mastectomy | 3 | 2000 | 1534 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 120 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2003 | 3536 | 0.020 |
Why?
|
| Brachiocephalic Trunk | 1 | 2004 | 43 | 0.020 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2004 | 6 | 0.020 |
Why?
|
| Biodegradation, Environmental | 1 | 2004 | 19 | 0.020 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 41 | 0.020 |
Why?
|
| Vena Cava, Superior | 1 | 2004 | 78 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1986 | 621 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2005 | 169 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 2195 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2007 | 583 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2000 | 4233 | 0.010 |
Why?
|
| Decision Trees | 1 | 2004 | 178 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 882 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 771 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2005 | 327 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2005 | 98 | 0.010 |
Why?
|
| Carcinoma, Large Cell | 1 | 2003 | 94 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 285 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2007 | 447 | 0.010 |
Why?
|
| Apoptosis | 3 | 2003 | 7591 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13310 | 0.010 |
Why?
|
| Intubation, Intratracheal | 2 | 1998 | 445 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 925 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.010 |
Why?
|
| Dogs | 3 | 1989 | 1155 | 0.010 |
Why?
|
| Heart | 1 | 2009 | 1223 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2003 | 243 | 0.010 |
Why?
|
| Gene Expression | 2 | 2000 | 3570 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 2002 | 87 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 321 | 0.010 |
Why?
|
| United Kingdom | 1 | 2002 | 257 | 0.010 |
Why?
|
| Aztreonam | 1 | 2001 | 14 | 0.010 |
Why?
|
| Piperacillin | 1 | 2001 | 29 | 0.010 |
Why?
|
| Amikacin | 1 | 2001 | 34 | 0.010 |
Why?
|
| Clindamycin | 1 | 2001 | 50 | 0.010 |
Why?
|
| Mitomycins | 2 | 1991 | 48 | 0.010 |
Why?
|
| Taxoids | 1 | 2004 | 967 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 1037 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 128 | 0.010 |
Why?
|
| Aorta | 1 | 2004 | 692 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 573 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 2000 | 175 | 0.010 |
Why?
|
| Nervous System | 1 | 2001 | 165 | 0.010 |
Why?
|
| Thoracostomy | 1 | 2000 | 43 | 0.010 |
Why?
|
| Pain | 2 | 1999 | 1658 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2000 | 164 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2000 | 289 | 0.010 |
Why?
|
| Heart-Assist Devices | 1 | 1989 | 1171 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 4917 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 181 | 0.010 |
Why?
|
| Laminectomy | 1 | 1999 | 52 | 0.010 |
Why?
|
| Pregnancy | 1 | 2012 | 7573 | 0.010 |
Why?
|
| Decompression, Surgical | 1 | 2000 | 143 | 0.010 |
Why?
|
| Ontario | 1 | 1999 | 98 | 0.010 |
Why?
|
| World Health Organization | 1 | 2000 | 316 | 0.010 |
Why?
|
| Methylmethacrylates | 1 | 1998 | 16 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2000 | 303 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2000 | 383 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2001 | 665 | 0.010 |
Why?
|
| Etoposide | 1 | 2001 | 870 | 0.010 |
Why?
|
| Mitral Valve | 1 | 2000 | 271 | 0.010 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 1998 | 19 | 0.010 |
Why?
|
| Kyphosis | 1 | 1998 | 43 | 0.010 |
Why?
|
| Back Pain | 1 | 1998 | 61 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 1998 | 46 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1998 | 54 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1999 | 287 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1998 | 57 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 1998 | 35 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2000 | 429 | 0.010 |
Why?
|
| Respiration, Artificial | 2 | 1993 | 577 | 0.010 |
Why?
|
| Genes, fos | 1 | 1998 | 53 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2000 | 699 | 0.010 |
Why?
|
| E2F4 Transcription Factor | 1 | 1998 | 30 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2000 | 694 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 446 | 0.010 |
Why?
|
| Rhodamines | 1 | 1998 | 49 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 1998 | 132 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1945 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 419 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1998 | 329 | 0.010 |
Why?
|
| Masks | 1 | 1998 | 57 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 842 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 675 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2003 | 986 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2000 | 604 | 0.010 |
Why?
|
| Muscle Weakness | 1 | 1998 | 116 | 0.010 |
Why?
|
| Spinal Nerve Roots | 1 | 1997 | 65 | 0.010 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1997 | 95 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1998 | 160 | 0.010 |
Why?
|
| Replication Protein C | 1 | 1997 | 18 | 0.010 |
Why?
|
| Locomotion | 1 | 1997 | 84 | 0.010 |
Why?
|
| Age Distribution | 1 | 1999 | 698 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2000 | 374 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 830 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 1487 | 0.010 |
Why?
|
| Mice | 2 | 2014 | 34495 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 1997 | 110 | 0.010 |
Why?
|
| Isomerism | 1 | 1996 | 63 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1999 | 694 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1997 | 166 | 0.010 |
Why?
|
| Data Collection | 1 | 1999 | 620 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1997 | 142 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2006 | 2669 | 0.010 |
Why?
|
| Walking | 1 | 1998 | 277 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1995 | 79 | 0.010 |
Why?
|
| Laparotomy | 1 | 1997 | 211 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2000 | 1014 | 0.010 |
Why?
|
| Weight Loss | 1 | 2000 | 627 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1995 | 97 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 159 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1998 | 467 | 0.010 |
Why?
|
| Plasmids | 1 | 1998 | 837 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1995 | 71 | 0.010 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1996 | 116 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1995 | 145 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2000 | 554 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1997 | 575 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 1824 | 0.010 |
Why?
|
| Benzoates | 1 | 1996 | 136 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2000 | 1385 | 0.010 |
Why?
|
| Luciferases | 1 | 1996 | 445 | 0.010 |
Why?
|
| Axilla | 1 | 1998 | 902 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1995 | 61 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2000 | 1688 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1998 | 329 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1995 | 114 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 7226 | 0.010 |
Why?
|
| Cell Count | 1 | 1995 | 508 | 0.010 |
Why?
|
| Survivors | 1 | 2000 | 1031 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1997 | 575 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2000 | 1271 | 0.010 |
Why?
|
| Heterozygote | 1 | 1997 | 1020 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 1399 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1999 | 1234 | 0.010 |
Why?
|
| Vomiting | 1 | 1995 | 354 | 0.010 |
Why?
|
| Protein Kinases | 1 | 1998 | 874 | 0.010 |
Why?
|
| Nausea | 1 | 1995 | 525 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1995 | 295 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1994 | 310 | 0.010 |
Why?
|
| Intestines | 1 | 1997 | 686 | 0.010 |
Why?
|
| Ribs | 1 | 1993 | 91 | 0.010 |
Why?
|
| Acute Disease | 1 | 1998 | 2422 | 0.010 |
Why?
|
| DNA Replication | 1 | 1997 | 744 | 0.010 |
Why?
|
| Fever | 1 | 1995 | 497 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1997 | 779 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1999 | 4804 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 3203 | 0.010 |
Why?
|
| Menopause | 1 | 1991 | 159 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1998 | 1756 | 0.010 |
Why?
|
| Inflammation | 1 | 2000 | 2522 | 0.010 |
Why?
|
| Cost Control | 1 | 1990 | 48 | 0.010 |
Why?
|
| Leuprolide | 1 | 1989 | 65 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 4314 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1988 | 12 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1998 | 2488 | 0.010 |
Why?
|
| Sheep | 1 | 1989 | 258 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1989 | 600 | 0.010 |
Why?
|
| Cytarabine | 1 | 1995 | 1973 | 0.010 |
Why?
|
| Heart Valves | 1 | 1988 | 66 | 0.010 |
Why?
|
| Breast | 1 | 1995 | 1344 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1989 | 291 | 0.000 |
Why?
|
| Muscle Tonus | 1 | 1987 | 13 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1988 | 295 | 0.000 |
Why?
|
| Sensation | 1 | 1987 | 71 | 0.000 |
Why?
|
| Rats | 1 | 1995 | 6086 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1998 | 4053 | 0.000 |
Why?
|
| Electromyography | 1 | 1987 | 226 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1987 | 426 | 0.000 |
Why?
|
| Cerebral Palsy | 1 | 1987 | 63 | 0.000 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1990 | 473 | 0.000 |
Why?
|
| Posture | 1 | 1987 | 215 | 0.000 |
Why?
|
| Tremor | 1 | 1987 | 128 | 0.000 |
Why?
|
| Equipment Design | 1 | 1989 | 1204 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 5539 | 0.000 |
Why?
|
| Movement | 1 | 1987 | 556 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1988 | 708 | 0.000 |
Why?
|
| Internship and Residency | 1 | 1994 | 1375 | 0.000 |
Why?
|
| Myocardium | 1 | 1989 | 1313 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1987 | 846 | 0.000 |
Why?
|
| Echocardiography | 1 | 1987 | 1182 | 0.000 |
Why?
|
| Heart Diseases | 1 | 1987 | 732 | 0.000 |
Why?
|
| Fatigue | 1 | 1987 | 1239 | 0.000 |
Why?
|